Literature DB >> 6123593

A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain.

D T Wong, P G Threlkeld, K L Best, F P Bymaster.   

Abstract

LY135252, (+/-)-N-methyl-gamma-(2-methylphenoxy) phenylpropylamine hydrochloride, is a competitive inhibitor of norepinephrine uptake in synaptosomes of rat hypothalamus. The resolved optical (-)-isomer, LY139603, is 2 and 9 times more effective than the racemate and the (+)-isomer, LY139602, with inhibitor constants (Ki) of 1.9, 3.4 and 16.8 nM, respectively. All three compounds are relatively weak in the inhibition of dopamine and serotonin uptake, with Ki values at least two orders of magnitude greater. The racemate and the two optical isomers in vivo are potent inhibitors of norepinephrine uptake with relative effectiveness being parallel with their K1 values. The most potent and long-acting compound was the (-)-isomer, LY139603, which inhibited norepinephrine uptake ex vivo with an ED50 value of 2.2 mg/kg i.p, and a half-life of 6.4 hr. In comparison with the tricyclic antidepressants desipramine and imipramine, LY139603 is a relatively weak ligand for alpha-1, alpha-2, and beta adrenergic receptors, acetylcholine-muscarinic receptors, histaminergic H1 receptors and the receptors of gamma-aminobutyric acid and benzodiazepines. Thus, LY139603 is a remarkably specific inhibitor of norepinephrine uptake. Its potential as an antidepressant is discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6123593

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  55 in total

1.  Characterization of the [3H]-desipramine binding site of the bovine adrenomedullary plasma membrane.

Authors:  J Michael-Hepp; B Blum; H Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-08       Impact factor: 3.000

2.  Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates.

Authors:  Jean-Dominique Gallezot; David Weinzimmer; Nabeel Nabulsi; Shu-Fei Lin; Krista Fowles; Christine Sandiego; Timothy J McCarthy; R Paul Maguire; Richard E Carson; Yu-Shin Ding
Journal:  Neuroimage       Date:  2010-09-30       Impact factor: 6.556

3.  Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.

Authors:  Benjamin L Handen; Michael G Aman; L Eugene Arnold; Susan L Hyman; Rameshwari V Tumuluru; Luc Lecavalier; Patricia Corbett-Dick; Xueliang Pan; Jill A Hollway; Kristin A Buchan-Page; Laura B Silverman; Nicole V Brown; Robert R Rice; Jessica Hellings; Daniel W Mruzek; Sarah McAuliffe-Bellin; Elizabeth A Hurt; Melissa M Ryan; Lynne Levato; Tristram Smith
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2015-09-03       Impact factor: 8.829

4.  A liquid chromatography/tandem mass spectrometry assay for the analysis of atomoxetine in human plasma and in vitro cellular samples.

Authors:  David I Appel; Bryan Brinda; John S Markowitz; Jeffrey H Newcorn; Hao-Jie Zhu
Journal:  Biomed Chromatogr       Date:  2012-01-25       Impact factor: 1.902

Review 5.  Psychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder.

Authors:  Craig W Berridge; David M Devilbiss
Journal:  Biol Psychiatry       Date:  2010-09-26       Impact factor: 13.382

6.  An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients.

Authors:  G Chouinard; L Annable; J Bradwejn
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 7.  Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.

Authors:  Dene Simpson; Greg L Plosker
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Atomoxetine reverses attentional deficits produced by noradrenergic deafferentation of medial prefrontal cortex.

Authors:  Lori A Newman; Jenna Darling; Jill McGaughy
Journal:  Psychopharmacology (Berl)       Date:  2008-06-22       Impact factor: 4.530

Review 9.  Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Authors:  Karly P Garnock-Jones; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

10.  Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents: a review.

Authors:  Paul Hammerness; Katherine McCarthy; Elizabeth Mancuso; Cassandra Gendron; Daniel Geller
Journal:  Neuropsychiatr Dis Treat       Date:  2009-04-08       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.